Trade Curis, Inc. - CRIS CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.1848 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001124% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 0.01 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 3.1076 |
| Open | 3.1876 |
| 1-Year Change | -72.42% |
| Day's Range | 3.1876 - 3.3476 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Jan 17, 2025 | 3.2076 | 0.0200 | 0.63% | 3.1876 | 3.3476 | 3.1376 |
| Jan 16, 2025 | 3.1076 | -0.0900 | -2.81% | 3.1976 | 3.1976 | 3.0876 |
| Jan 15, 2025 | 3.1876 | 0.0800 | 2.57% | 3.1076 | 3.2476 | 3.1076 |
| Jan 14, 2025 | 3.1376 | -0.0800 | -2.49% | 3.2176 | 3.2676 | 3.1276 |
| Jan 13, 2025 | 3.2676 | -0.0100 | -0.31% | 3.2776 | 3.3076 | 3.1476 |
| Jan 10, 2025 | 3.3476 | -0.1000 | -2.90% | 3.4476 | 3.5076 | 3.3076 |
| Jan 8, 2025 | 3.4176 | -0.0400 | -1.16% | 3.4576 | 3.5076 | 3.2376 |
| Jan 7, 2025 | 3.5976 | 0.1500 | 4.35% | 3.4476 | 3.6676 | 3.3476 |
| Jan 6, 2025 | 3.4676 | -0.2700 | -7.22% | 3.7376 | 3.8176 | 3.4476 |
| Jan 3, 2025 | 3.8276 | -0.3100 | -7.49% | 4.1376 | 4.3676 | 3.5876 |
| Jan 2, 2025 | 4.2476 | 0.4500 | 11.85% | 3.7976 | 4.4576 | 3.3076 |
| Dec 31, 2024 | 3.0076 | 0.0100 | 0.33% | 2.9976 | 3.1476 | 2.8076 |
| Dec 30, 2024 | 3.0376 | -0.1000 | -3.19% | 3.1376 | 3.1576 | 3.0376 |
| Dec 27, 2024 | 3.1476 | -0.0400 | -1.25% | 3.1876 | 3.2176 | 3.0576 |
| Dec 26, 2024 | 3.0476 | -0.0200 | -0.65% | 3.0676 | 3.1976 | 3.0476 |
| Dec 24, 2024 | 3.1276 | 0.0100 | 0.32% | 3.1176 | 3.1676 | 3.0576 |
| Dec 23, 2024 | 3.1876 | 0.0200 | 0.63% | 3.1676 | 3.4576 | 3.0676 |
| Dec 20, 2024 | 3.1176 | 0.0800 | 2.63% | 3.0376 | 3.1376 | 2.9776 |
| Dec 19, 2024 | 3.0476 | -0.1300 | -4.09% | 3.1776 | 3.1976 | 2.9976 |
| Dec 18, 2024 | 3.1976 | -0.2000 | -5.89% | 3.3976 | 3.4476 | 3.1876 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Curis, Inc. Company profile
About Curis, Inc.
Curis, Inc. is a biotechnology company focused on the development of therapeutics for the treatment of cancer. The Company’s drug candidates include CA-4948 and CI-8993. CA-4948 is an orally available small-molecule inhibitor of Interleukin-I receptor-associated kinase 4, which is undergoing testing in a Phase I open-label dose escalating clinical trial in patients with non-Hodgkin lymphomas. It is also conducting a Phase I open-label, single-arm dose escalating trial in patients with acute myeloid leukemia, and myelodysplastic syndromes. CI-8993 is a monoclonal antibody designed to antagonize the V-domain Ig suppressor of the T cell activation signaling pathway. The Company initiated a Phase Ia/Ib trial of CI-8993 in patients with solid tumors. The Company’s products pipeline includes Fimepinostat, CA-170, CA-327, and PD1/TIM3 Program.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Curis, Inc. revenues decreased 2% to $10.6M. Net loss increased 52% to $45.4M. Revenues reflect Other revenue decrease of 100% to $1K. Higher net loss reflects Research & development Expenses B/F increase of 50% to $32M (expense), Other General and administrative, increase of 43% to $8M (expense), General and administrative expenses increase of 75% to $3.4M (expense).
Equity composition
Common Stock $.01 Par, 03/11, 125M auth., 77,397,663 issd., less 1,047,707 shs. in tres. @ $891K. Insiders own 2.72%. IPO 12/92, 3M shs. @ $7 by Montgomery Secs. *8/00, Co.merged with Ontogeny & Reprogenesis & chgd. name from Creative Biomolecules, Inc. FY'03&'04 are RES-Acct. Change. Summ. Qs reflects RES.
| Industry: | Biotechnology & Medical Research (NEC) |
128 Spring Street
4 Maguire Road
LEXINGTON
MASSACHUSETTS 02421
US
News
Ethereum price prediction: Third party data round up
What is the outlook for ETH as a long-term investment?
16:37, 7 January 2025
Euro forecast: third party data roundup
In 2024, the euro’s outlook appeared more stable. Read on for our 2025 and beyond insights.
12:40, 31 December 2024
Pi Network coin price prediction: Third party price target
Discover the Pi Network coin price predictions for 2025 onward, with analyst outlooks, price targets and CFDs trading strategies on Capital.com
13:51, 13 December 2024
Projected US interest rates in 5 years: Third party round up
As the US central bank starts its cutting cycle, what are the projected interest rates in 5 years?
14:28, 12 December 2024
Projected UK interest rates in 5 years
Bank of England (BoE) cut rates for the first time in August 2024, with further easing expected in the coming months. But how low are rates likely to go?
11:20, 12 December 2024
Dogecoin (DOGE) price prediction 2025-2030: Could Dogecoin reach $1? - Third party price target
We look at the meme coin’s price performance and the latest DOGE price predictions
08:37, 12 December 2024
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
09:13, 6 December 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com